ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events

ME Staff 8-k
-
0

ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events
Item 8.01 Other Events

On May 4, 2017, ContraVir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing it is developing a second-generation formulation of TXL™, the Company’s proprietary liver-targeting prodrug of the antiviral agent tenofovir for treating chronic HBV.

The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

99.1 ContraVir Pharmaceuticals, Inc. Press Release dated May 4, 2017


About ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Recent Trading Information

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) closed its last trading session down -0.021 at 0.809 with 1,811,668 shares trading hands.